The association between antiphospholipid antibodies and placenta mediated complications: A systematic review and meta-analysis

Thrombosis Research

Volumn 128, Issue 1, 2011, Pages 77-85

  Abou Nassar, Karim ^a   Carrier, Marc ^a,b   Ramsay, Tim ^b   Rodger, Marc A ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY;

ARTICLE; CASE CONTROL STUDY; DISEASE ASSOCIATION; FETUS WASTAGE; HUMAN; PREECLAMPSIA; PREGNANCY; PRENATAL GROWTH; PRIORITY JOURNAL; SOLUTIO PLACENTAE; STILLBIRTH; SYSTEMATIC REVIEW;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMANS; PLACENTA; PLACENTA DISEASES; PREGNANCY;

EID: 79958045457     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.02.006     Document Type: Article

References (53)

1. Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun 2000;15:145-51.
2. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1, 000 patients. Medicine (Baltimore) 1993;72:113-24. (Pubitemid 23097765)
3. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders: prevalence and clinical significance. Ann Intern Med 1990;112:682-98. (Pubitemid 20137178)
4. Lockwood CJ, Romero R, Feinberg RF, Clyne LP, Coster B, Hobbins JC. The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population. Am J Obstet Gynecol Aug 1989;161(2):369-73.
5. Lynch A, Marlar R, Murphy J, Davila G, Santos M, Rutledge J, et al. Antiphospholipid antibodies in predicting adverse pregnancy outcome. A prospective study. Ann Intern Med 1994;120:470-5. (Pubitemid 24075224)
6. Yasuda M, Takakuwa K, Tokunaga A, Tanka K. Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy. Obstet Gynecol 1995;86:555-9.
7. Tsapanos V, Kanellopoulos N, Cardamakis E, Fotopoulos A, Schinas V, Kondakis X, et al. Anticardiolipin antibodies levels in healthy pregnant and non-pregnant woman. Arch Gynecol Obstet 2000;263(3):111-5. (Pubitemid 30153704)
8. Matthiesen LS, Berg G, Ernerudh J, Skogh T. A prospective study on the occurrence of autoantibodies in low-risk pregnancies. Eur J Obstet Gynecol Reprod Biol 1999;83(1):21-6. (Pubitemid 29101568)
9. Hughes GRV, Harris EN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol 1986;13:486-9.
10. Alarcón-Segovia D, Delezé M, Oria CV, Sanchez-Guerrero J, Gomez-Pacheco L, Cabiedes J, et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus: a prospective analysis of 500 consecutive patients. Medicine (Baltimore) 1989;68:353-65.
11. Robertson L, Wu O, Langhorne P, Twaddle S, Clark P, Lowe GD, et al. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006;132(2):171-96.
12. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International conssensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999;42:1309-11. (Pubitemid 30265586)
13. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
14. Opatrny L, David M, Kahn SR, Shrier I, Rey E. Association Between Antiphospholipid Antibodies and Recurrent Fetal Loss in Women Without Autoimmune Disease: A Metaanalysis. J Rheumatol 2006;33(11):2214-21. (Pubitemid 44749780)
15. Reber G, Tincani A, Sanmarco M, de Moerloose P, Boffa MC. Proposals for the measurement of anti-beta2-glycoprotein 1 antibodies. Standardization group of the European Forumon AntiphospholipidAntibodies. J ThrombHaemost 2004;2:1860-2.
16. Kramer MS, Platt RW, Wen SW, Joseph KS, Allen A, Abrahamowicz M, et al. A new and improved population-based Canadian reference for birth weight for gestational age. Pediatrics 2001;108(2):E35.
17. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical-epidemiology/oxford.htm.
18. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58. (Pubitemid 34746062)
19. Alfirevic Z, Mousa HA, Martlew V, Briscoe L, Perez-Casal M, Toh CH. Postnatal screening for thrombophilia in women with severe pregnancy complications. Obstet Gynecol 2001;97(5pt 1):753-9.
20. Bocciolone L, Meroni P, Parazzini F, Tincani A, Radici E, Tarantani M, et al. Antiphospholipid antibodies and risk of intrauterine fetal death. Acta Obstet Gynecol Scand 1994;73:389-92. (Pubitemid 24164418)
21. Dreyfus M, Hedelin G, Kutnahorsky R, Lehmann M, Viville B, Langer B, et al. Antiphospholipid antibodies and preeclampsia: a case-control study. Obstet Gynecol 2001;97:29-34. (Pubitemid 32057151)
22. Kaleli B, Kaleli I, Aktan E, Turan C, Aksit F. Antiphospholipid antibodies in eclamptic women. Gynecol Obstet Invest 1998;45:81-4. (Pubitemid 28075861)
23. Mello G, Parretti E, Martini E, Mecacci F, La Torre P, Cioni R, et al. Haemostasis 1999;29:197-203.
24. Milliez J, Lelong F, Bayani N, Jannet D, El Medjadi M, Latrous H, et al. The prevalence of autoantibodies during third-trimester pregnancy complicated by hypertension or idiopathic fetal growth restriction. Am J Obstet Gynecol 1991;165:51-6.
25. Moodley J, Bhoola V, Duursma J, Pudifin D, Byrne S, Kenoyer DG. The association of antiphospholipid antibodies with severe early-onset pre-eclampsia. S Afr Med J 1995;85:105-7.
26. Pattison NS, Chamley LW, McKay EJ, Liggins GC, Butler WS. Antiphospholipid antibodies in pregnancy: prevalence and clinical associations. Br J Obstet Gynaecol 1993;100:909-13. (Pubitemid 23308274)
27. Rix P, Stentoft J, Aunsholt NA, Dueholm M, Andersen Tilma K, Høier-Madsen M. Lupus anticoagulant and anticardiolipin antibodies in an obstetric population. Acta Obstet Gynecol Scand 1992;71:605-9. (Pubitemid 23050340)
28. Schjetlein R, Haugen G, Moe N, Husby H, Wisløff F. Preeclampsia and fetal growth retardation: is there an association with antiphospholipid antibodies? Hypertens Pregnancy 1998;17(1):81-92.
29. Vahid F, Ayatiy S, Shakeri MT. Comparison of antiphospholipid antibodies between preeclamptsia and normal pregnant women. Iran J Med Sci 2006;31(1):47-9. (Pubitemid 43352423)
30. Wharfe G, Fletcher H, Reid M. Lupus anticoagulant in Jamaican primipare and the clinical significance in asymptomatic patients.West IndianMed J 1999;48(3):126-8.
31. Allen JY, Tapia-Santiago C, Kuetth WH. Antiphospholipid antibodies and patients with preeclampsia. Am J Reprod Immunol 1996;36:81-5.
32. Bowen RS, Moodley J, Dutton MF, Fickl H. Antibodies to oxidized low density lipoproteins and cardiolipin in pre-eclampsia and eclampsia. J Obstet Gynaecol 2002;184(5):825-32.
33. Faden D, Tincani A, Tanzi P, Spatola L, Lojacono A, Tarantini M, et al. Anti-beta 2 glycoprotein I antibodies in a general obstetric population: preliminary results on the prevalence and correlation with pregnancy outcome. Anti-beta2 glycoprotein I antibodies are associated with some obstetrical complications, mainly preeclampsia-eclampsia. Eur J Obstet Gynecol Reprod Biol 1997;73(1):37-42. (Pubitemid 27224458)
34. Katano K, Aoki K, Sasa H, Ogasawara M, Matsuura E, Yagami Y. B2-Glycoprotein 1-dependant anticardiolipin antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women. Hum Reprod 1996;11(3):509-12. (Pubitemid 26125247)
35. Lee RM, Brown MA, Branch DW, Ward K, Silver RM. Anticardiolipin and antibeta2- glycoprotein-I antibodies in preeclampsia. Obstet Gynecol 2003;102(2):294-300. (Pubitemid 36937000)
36. Lee R, Emlen W, Scott JR, Branch W, Silver RM. Anti-B2 Glycoprotein 1 antobodies and women with recurrent spontaneous abortions, unexplained fetal death, and antiphospholipid syndrome. Am J Obstet Gynceol 1999;181(3):642-8. (Pubitemid 29453527)
37. Lynch AM, Rutledge JH, Stephens JK, Murphy JR, Marlar RA, Davila GH, et al. Longitudinal measurement of anticardiolipin antibodies during normal pregnancy: a prospective study. Lupus 1995;4:365-9.
38. Stuart RA, Kornman LH, McHugh NJ. A prospective study of pregnancy outcome in women screened at a routine antenatal clinic for anticardiolipin antibodies. Br J Obstet Gynaecol 1993;100:599-600. (Pubitemid 23186370)
39. Uncu G, Ozan H, Küçükerdoǧan I, Cengiz C. Anticardiolipin antibodies in pregnancy induced hypertension. Eur J Obstet Gynecol Reprod Biol 1996;70(1):97-100. (Pubitemid 27041949)
40. Valdes-Macho E, Cabiedes J, Villa AR, Cabral AR, Alarcon-Segovia D. Anticardiolipin and antibeta2-glycoprotein-I antibodies in hypertensive disorders of pregnancy. Arch Med Res 2002;33(5):460-5. (Pubitemid 35397261)
41. van Pampus MG, Dekker GA, Wolf H, Huijgens PC, Koopman MM, von Blomberg BM, et al. High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia. Am J Obstet Gynecol 1999;180(5):1146-50. (Pubitemid 29259008)
42. Yamamoto T, Yoshimura S, Geshi Y, Sasamori Y, Okinaga S, Kobayashi T, et al. Antiphospholipid antibodies in preeclampsia and their binding ability for placental villous lipid fractions. J Obstet Gynaecol Res 1996;22(3):275-83. (Pubitemid 126450137)
43. De Carolis S, Caruso A, Ferrazzani S, Carducci B, De Santis L, Mancuso S. Poor pregnancy outcomes and anticardiolipin antibodies. Fetal Diagn Ther 1994;9:296-9. (Pubitemid 24300741)
44. Vora S, Shetty S, Salvi V, Satoskar P, Ghosh K. A comprehensive screening analysis of antiphospholipid antibodies in Indian women with fetal loss. Eur J Obstet Gynecol Reprod Biol 2008;137(2):136-40. (Pubitemid 351423458)
45. Dereksen W, Erkan D, Kaplan V, Sammaritano L, Pierangeli SS, Lockshin MD. Real world experience with antiphospholipid antibodies (aPL): How stable are aPL over time? Arthritis Rheum 2004;50:S67.
46. Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 Suppl):844S-86S.
47. Sachs BP, Brown DA, Driscoll SG, Schulman E, Acker D, Ransil BJ, et al. Maternal mortality in Massachusetts. Trends and prevention. N Engl J Med 1987;316(11):667-72. (Pubitemid 17032952)
48. McColl MD, Ramsay JE, Tait RC, Walker ID, McCall F, Conkie JA, et al. Risk factors for pregnancyassociated venous thromboembolism. Thromb Haemost 1997;78(4):1183-8. (Pubitemid 27464583)
49. Helewa ME, Burrows RF, Smith J, Williams K, Brain P, Rabkin SW. Report of the Canadian Hypertension Society Consensus Conference: 1. Definitions, evaluation and classification of hypertensive disorders in pregnancy. CMAJ 1997;157:715-25.
50. Strauss RS, Dietz WH. Effects of intrauterine growth retardation in premature infants on early childhood growth. J Pediatr 1997;130(1):95-102. (Pubitemid 27492725)
51. Strauss RS. Effects of the intrauterine environment on childhood growth. Br Med Bull 1997;53:81-95. (Pubitemid 27129179)
52. Strauss RS, Dietz WH. Growth and development of term children born with low birth weight: effects of genetic and environmental factors. J Pediatr 1998;133(1):67-72. (Pubitemid 28323908)
53. Strauss RS. Adult functional outcome of those born small for gestational age: twenty-six-year followup of the 1970 British Birth Cohort. JAMA 2000;283(5):625-32.